omeprazole sold brand names prilosec losec among others medication used treatment gastroesophageal reflux disease gerd peptic ulcer disease also used prevent upper gastrointestinal bleeding people high omeprazole protonpump inhibitor ppi effectiveness similar taken mouth injection also available fixeddose combination medication omeprazolesodium bicarbonate common side effects include nausea vomiting headaches abdominal pain increased intestinal serious side effects may include clostridium difficile colitis increased risk pneumonia increased risk bone fractures potential masking stomach whether safe use pregnancy works blocking release stomach omeprazole patented approved medical use world health organizations list essential available generic eighthmost commonly prescribed medication united states million also available without prescription united omeprazole used treatment gastroesophageal reflux disease gerd peptic ulcers erosive esophagitis syndrome eosinophilic peptic ulcers may treated omeprazole infection helicobacter pylori treated taking omeprazole amoxicillin clarithromycin together amoxicillin may replaced metronidazole patients allergic adverse effects occurring least people verification concerns related adverse effects concern expressed regarding vitamin iron effects seem insignificant especially supplement therapy since introduction protonpump inhibitors ppis especially omeprazole also associated several cases acute interstitial inflammation kidneys often occurs adverse drug reaction longterm use ppis strongly associated development benign polyps fundic glands distinct fundic gland polyposis polyps cause cancer resolve ppis discontinued association seen ppi use cancer use ppis may mask gastric cancers serious gastric problems physicians aware possible association long term use dementia requires study review article us pharmacist states longterm use ppis associated decreased calcium absorption causing increased risk osteoporosis fractures decreased magnesium absorption causing electrolyte disturbances increased risk certain infections c difficile communityacquired pneumonia hypothesize due decreased stomach acid safety using omeprazole established pregnant breastfeeding epidemiological data show increased risk major birth defects maternal use omeprazole important drug interactions however significant major drug interaction concern decreased activation clopidogrel taken together although still may increase risk stroke heart attack people taking clopidogrel prevent events interaction possible omeprazole inhibitor enzymes clopidogrel inactive prodrug partially depends conversion active form inhibition may block activation clopidogrel could reduce almost benzodiazepines metabolised pathways inhibition enzymes results higher area curve ie total effect time given dose examples drugs dependent metabolism oxycodone tramadol oxymorphone concentrations drugs may increase used concomitantly omeprazole also competitive inhibitor pglycoprotein drugs depend acidic stomach environment ketoconazole atazanavir may poorly absorbed whereas acidlabile antibiotics erythromycin strong inhibitor may absorbed greater extent normal due alkaline environment st johns wort hypericum perforatum ginkgo biloba significantly reduce plasma concentrations omeprazole induction protonpump inhibitors like omeprazole found increase plasma concentrations omeprazole irreversibly blocks enzyme system parietal cells needed secretion gastric acid specific hkatpase inhibitor enzyme needed final step secretion gastric omeprazole selective irreversible proton pump inhibitor suppresses stomach acid secretion specific inhibition hkatpase system found secretory surface gastric parietal cells enzyme system regarded acid proton h pump within gastric mucosa omeprazole inhibits final step acid omeprazole also inhibits basal stimulated acid secretion irrespective blocks last step acid drug binds noncompetitively dosedependent inhibitory effect omeprazole occurs within hour oral administration maximum effect occurs within hours duration inhibition hours omeprazole stopped baseline stomach acid secretory activity returns days inhibitory effect omeprazole acid secretion plateau days repeated daily absorption omeprazole takes place small intestine usually completed within hours systemic bioavailability omeprazole repeated doses omeprazole volume distribution lkg high plasma protein binding omeprazole well ppis effective active hkatpase pumps pumps stimulated presence food aid digestion reason patients advised take omeprazole glass water empty additionally sources recommend taking omeprazole least minutes allowed elapse least minutes immediaterelease omeprazole plus sodium bicarbonate products omeprazole completely metabolized cytochrome system mainly liver identified metabolites sulfone sulfide hydroxyomeprazole exert significant effect acid secretion orally given dose excreted metabolites urine remainder found feces primarily originating bile omeprazole half life omeprazole contains tricoordinated sulfonyl sulfur pyramidal structure therefore exist either renantiomers omeprazole racemate equal mixture two acidic conditions canaliculi parietal cells enantiomers converted achiral products sulfenic acid sulfenamide configurations react cysteine group hk atpase thereby inhibiting ability parietal cells produce gastric acidcitation needed astrazeneca also developed esomeprazole nexium eutomer purely senantiomer rather racemate like omeprazolemedical citation needed omeprazole undergoes chiral shift vivo converts inactive renantiomer active senantiomer doubling concentration active chiral shift accomplished isozyme cytochrome found equally human populations metabolize drug effectively called poor metabolizers proportion poor metabolizer phenotype varies widely populations african americans white americans asians several pharmacogenomics studies suggested ppi treatment tailored according metabolism omeprazole may quantified plasma serum monitor therapy confirm diagnosis poisoning hospitalized patients plasma omeprazole concentrations usually range mgl persons receiving drug therapeutically oral route mgl people acute overdose enantiomeric chromatographic methods available distinguish esomeprazole racemic omeprazole first made swedish ab h√§ssle part astra ab first proton pump inhibitors astra ab astrazeneca launched ulcer medicine name losec sweden first sold united states brand name losec request us food drug administration brand name losec changed prilosec avoid confusion diuretic lasix new name led confusion omeprazole prilosec fluoxetine prozac prilosecs us patent expired april astrazeneca introduced esomeprazole nexium patented replacement many companies introduced generics astrazenecas patents expired worldwide available many brand names omeprazole subject patent litigation invention involved application two different coatings drug pill form ensure omeprazole disintegrate reaching intended site action stomach although solution means two coating obvious patent found valid source problem nonobvious discovered september astrazeneca announced would pay million settle product liability litigations prilosec united brand names include losec prilosec zegerid miracid httpsenwikipediaorgwikiomeprazole